A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

NCT05032157 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

455

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: LOU064 (blinded)
DRUG: Placebo
DRUG: LOU064 (open-label)

Sponsor

Novartis Pharmaceuticals